Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections

A variety of in-vitro and animal studies were performed to define the pharmacodynamic characteristics of amikacin against Gram-negative bacilli and to determine the impact of the dosing regimen on therapeutic efficacy. Mice with impaired renal function were included in these studies to more closely...

Full description

Saved in:
Bibliographic Details
Main Authors: Craig, WA, Redington, J, Ebert, S C
Format: Conference Proceeding
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page no. C sul.
container_issue
container_start_page no. C sul.
container_title
container_volume 27
creator Craig, WA
Redington, J
Ebert, S C
description A variety of in-vitro and animal studies were performed to define the pharmacodynamic characteristics of amikacin against Gram-negative bacilli and to determine the impact of the dosing regimen on therapeutic efficacy. Mice with impaired renal function were included in these studies to more closely simulate in animals the pharmacokinetics of amikacin observed in humans. Amikacin exhibited concentration-dependent killing and produced prolonged postantibiotic effects both in vitro and in vivo. In mice renal impairment, the efficacy of once-daily dosing of amikacin was similar to or greater than that observed with 6- and 12-hour dosing regimens. The antibacterial activity of amikacin in these mice correlated best with the AUC and peak serum concentration. The time course of antimicrobial activity demonstrated in these studies for amikacin against Gram-negative bacilli would support once-daily dosing in humans.
format conference_proceeding
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_16019207</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16019207</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_160192073</originalsourceid><addsrcrecordid>eNpjYeA0MDYw1TU3MTXmYOAqLs4yMDAwMzWz4GTwCchILMpNTM5PqcxLzM1MLlbIT1MAMrITkzPzFICoLLOkKF8hMS8FxMnNLy1OVSjJyEzPAAvllOalA8XTUpNLMvPzinkYWNMSc4pTeaE0N4Oam2uIs4duQVF-YWlqcUl8bmZxcmpOTmJeKtCkeEMzA0NLIwNzY6IVAgCLzkAl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>conference_proceeding</recordtype><pqid>16019207</pqid></control><display><type>conference_proceeding</type><title>Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections</title><source>Oxford University Press Archive</source><creator>Craig, WA ; Redington, J ; Ebert, S C</creator><contributor>Finch, RG ; Davey, PG ; Wood, MJ (eds)</contributor><creatorcontrib>Craig, WA ; Redington, J ; Ebert, S C ; Finch, RG ; Davey, PG ; Wood, MJ (eds)</creatorcontrib><description>A variety of in-vitro and animal studies were performed to define the pharmacodynamic characteristics of amikacin against Gram-negative bacilli and to determine the impact of the dosing regimen on therapeutic efficacy. Mice with impaired renal function were included in these studies to more closely simulate in animals the pharmacokinetics of amikacin observed in humans. Amikacin exhibited concentration-dependent killing and produced prolonged postantibiotic effects both in vitro and in vivo. In mice renal impairment, the efficacy of once-daily dosing of amikacin was similar to or greater than that observed with 6- and 12-hour dosing regimens. The antibacterial activity of amikacin in these mice correlated best with the AUC and peak serum concentration. The time course of antimicrobial activity demonstrated in these studies for amikacin against Gram-negative bacilli would support once-daily dosing in humans.</description><identifier>ISSN: 0305-7453</identifier><language>eng</language><ispartof>Journal of antimicrobial chemotherapy, 1991, Vol.27, p.no. C sul.-no. C sul.</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,780,784,789,790,23930,23931,25140</link.rule.ids></links><search><contributor>Finch, RG</contributor><contributor>Davey, PG</contributor><contributor>Wood, MJ (eds)</contributor><creatorcontrib>Craig, WA</creatorcontrib><creatorcontrib>Redington, J</creatorcontrib><creatorcontrib>Ebert, S C</creatorcontrib><title>Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections</title><title>Journal of antimicrobial chemotherapy</title><description>A variety of in-vitro and animal studies were performed to define the pharmacodynamic characteristics of amikacin against Gram-negative bacilli and to determine the impact of the dosing regimen on therapeutic efficacy. Mice with impaired renal function were included in these studies to more closely simulate in animals the pharmacokinetics of amikacin observed in humans. Amikacin exhibited concentration-dependent killing and produced prolonged postantibiotic effects both in vitro and in vivo. In mice renal impairment, the efficacy of once-daily dosing of amikacin was similar to or greater than that observed with 6- and 12-hour dosing regimens. The antibacterial activity of amikacin in these mice correlated best with the AUC and peak serum concentration. The time course of antimicrobial activity demonstrated in these studies for amikacin against Gram-negative bacilli would support once-daily dosing in humans.</description><issn>0305-7453</issn><fulltext>true</fulltext><rsrctype>conference_proceeding</rsrctype><creationdate>1991</creationdate><recordtype>conference_proceeding</recordtype><recordid>eNpjYeA0MDYw1TU3MTXmYOAqLs4yMDAwMzWz4GTwCchILMpNTM5PqcxLzM1MLlbIT1MAMrITkzPzFICoLLOkKF8hMS8FxMnNLy1OVSjJyEzPAAvllOalA8XTUpNLMvPzinkYWNMSc4pTeaE0N4Oam2uIs4duQVF-YWlqcUl8bmZxcmpOTmJeKtCkeEMzA0NLIwNzY6IVAgCLzkAl</recordid><startdate>19910101</startdate><enddate>19910101</enddate><creator>Craig, WA</creator><creator>Redington, J</creator><creator>Ebert, S C</creator><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>19910101</creationdate><title>Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections</title><author>Craig, WA ; Redington, J ; Ebert, S C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_160192073</frbrgroupid><rsrctype>conference_proceedings</rsrctype><prefilter>conference_proceedings</prefilter><language>eng</language><creationdate>1991</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Craig, WA</creatorcontrib><creatorcontrib>Redington, J</creatorcontrib><creatorcontrib>Ebert, S C</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Craig, WA</au><au>Redington, J</au><au>Ebert, S C</au><au>Finch, RG</au><au>Davey, PG</au><au>Wood, MJ (eds)</au><format>book</format><genre>proceeding</genre><ristype>CONF</ristype><atitle>Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections</atitle><btitle>Journal of antimicrobial chemotherapy</btitle><date>1991-01-01</date><risdate>1991</risdate><volume>27</volume><spage>no. C sul.</spage><epage>no. C sul.</epage><pages>no. C sul.-no. C sul.</pages><issn>0305-7453</issn><abstract>A variety of in-vitro and animal studies were performed to define the pharmacodynamic characteristics of amikacin against Gram-negative bacilli and to determine the impact of the dosing regimen on therapeutic efficacy. Mice with impaired renal function were included in these studies to more closely simulate in animals the pharmacokinetics of amikacin observed in humans. Amikacin exhibited concentration-dependent killing and produced prolonged postantibiotic effects both in vitro and in vivo. In mice renal impairment, the efficacy of once-daily dosing of amikacin was similar to or greater than that observed with 6- and 12-hour dosing regimens. The antibacterial activity of amikacin in these mice correlated best with the AUC and peak serum concentration. The time course of antimicrobial activity demonstrated in these studies for amikacin against Gram-negative bacilli would support once-daily dosing in humans.</abstract></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 1991, Vol.27, p.no. C sul.-no. C sul.
issn 0305-7453
language eng
recordid cdi_proquest_miscellaneous_16019207
source Oxford University Press Archive
title Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A26%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=proceeding&rft.atitle=Pharmacodynamics%20of%20amikacin%20in%20vitro%20and%20in%20mouse%20thigh%20and%20lung%20infections&rft.btitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Craig,%20WA&rft.date=1991-01-01&rft.volume=27&rft.spage=no.%20C%20sul.&rft.epage=no.%20C%20sul.&rft.pages=no.%20C%20sul.-no.%20C%20sul.&rft.issn=0305-7453&rft_id=info:doi/&rft_dat=%3Cproquest%3E16019207%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_160192073%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16019207&rft_id=info:pmid/&rfr_iscdi=true